Table 1.
ADCs involving in clinical trials on cancers treatment.
| Trial | Phase | Patients (n) | Drugs | ORR,% (95% CI) |
mPFS, months (95% CI) |
mOS, months (95% CI) |
Ref. |
|---|---|---|---|---|---|---|---|
| KSCC/HGCSG/CCOG/CCOG/PerSeUS 1501B | II | 42 | T-Mab | 82.1 (95% CI 70.0 -90.0) |
7.0 (95% CI 5.5-14.1) |
27.6 (95% CI 15.6-NR) |
(30) |
| GATSBY | II/III | 415 | T-DM1 | 20.6 (95%CI 15.3-25.8) |
2.7 (95%CI 1.61-2.79) |
7.9 (95%CI 6.7-7.9) |
(31) |
| PTX | 19.6 (95%CI 13.7-25.5) |
2.9 (95%CI 2.76-4.01) |
8.6 (95% CI 7.1-11.2) |
||||
| NCT02564900 | I | 54 | T-DXd | 37 (95%CI 24.3-51.3) |
11.1 (95% CI 7.6-NR) |
29.4 (95% CI 12.9-29.4) |
(32) |
| DESTINY-Gastric01 | I | 187 | DS-8201 | 51.3 (95% CI 41.9-60.5) |
5.6 (95% CI 4.3-6.9) |
12.5 (95% CI 10.3-15.2) |
(33) |
| Chemotherapy | 14.3 (95% CI6.4-26.2) |
3.5 (95% CI 2.0-4.3) |
8.4 (95% CI 6.4-10.4) |
||||
| DESTINY-Gastric02 | II | 79 | DS-8201 | 38 (95% CI 27.3-49.6) |
5.6 (95% CI4.2-8.3) |
12.1 (95% CI 9.4-15.4) |
(34) |
| NCT02881190 | I | 57 | RC48 | 23.6 (95% CI 18.3-28.9) |
– | 12.6 (95% CI 9.8-15.6) |
(35) |
| RC48-C008 | II | 125 | RC48-ADC | 18.1 (95%CI 11.8-25.9) |
3.8 (95% CI 2.7-4.0) |
7.6 (95% CI 6.6-9.2) |
(36) |
| CTR20190639 | I | 30 | ARX788 | 37.9 (95% CI 20.7-57.7) |
10.7 (95% CI: 4.8-NR) |
4.1 (95% CI 1.4-6.4) |
(37) |
| NCT04868344 | I | 39 | MRG003 | 75 (95%CI 50.9-91.3) |
2.8 (95%CI 1.2-4.1) |
11.8 (95%CI 3.4-11.8) |
(38) |